## EFX: Equifax, Inc. - XLI: Industrials

### Executive Summary

No thesis match: PEG 1.02 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($206.08)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Lazard Asset Management LLC Buys 140,427 Shares of Equifax, Inc. $EFX**
- Source: MarketBeat | 20251214T134158 | Neutral | Relevance: 96%
- Lazard Asset Management LLC increased its stake in Equifax (NYSE:EFX) by 8.9% in Q2, acquiring 140,427 additional shares, bringing its total holdings to 1,726,990 shares valued at approximately $447.9 million. This move comes as several insiders, including CEO Mark W. Begor and EVP Jamil Farshchi, have sold shares, though analysts maintain a "Moderate Buy" rating with a consensus target price of $276.40. Equifax reported strong Q3 earnings, beating estimates, and declared a quarterly dividend of $0.50.

**2. Veriskâ€“KYND Cyber Data Tie-Up Might Change The Case For Investing In Verisk Analytics (VRSK)**
- Source: Simply Wall Street | 20251214T193851 | Neutral | Relevance: 62%
- Verisk's expanded collaboration with KYND integrates KYND's cyber risk intelligence into Verisk's Rulebook platform, aiming to strengthen Verisk's cyber offering for insurers. This partnership addresses the increasing demand for advanced cyber risk data, potentially influencing Verisk's long-term growth and product differentiation by deepening its role in insurers' workflows. However, the impact on Verisk's revenue will depend on how quickly insurance clients adopt these analytics services, especially after a period of softer revenue.

**3. Verisk Analytics (VRSK) Valuation After Q3 Revenue Miss, Outlook Cut and Expanded KYND Cyber Partnership**
- Source: Simply Wall Street | 20251216T122504 | Neutral | Relevance: 56%
- Verisk Analytics (VRSK) is facing mixed signals after missing Q3 revenue expectations and cutting its full-year outlook, despite expanding its KYND cyber partnership. While its share price is suffering near-term, long-term faith seems intact, with the stock trading below intrinsic estimates and analyst targets. Investors are now evaluating whether this presents a mispriced opportunity or if the market is accurately discounting future growth.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | BMO Capital | $234 | $245 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | BMO Capital | main | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.90M) |
| Sells | 5 ($1.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+2.1%)
- Capital Internationa: 8.5% (-0.4%)
- Blackrock Inc.: 7.5% (+1.4%)
- Price (T.Rowe) Assoc: 4.9% (+1.0%)
- Harris Associates L.: 4.8% (+14.2%)

### Key Risks

1. Long-term trend broken: trading 10.6% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +5.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.02 suggests fair value with growth premium. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.7B |
| Beta | 1.59 |
| 52W Range | $199.98 - $281.07 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.02 |
| Forward P/E | 24.6 |
| Current P/E | 28.5 |
| YoY Growth | 16.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.7% to 3.4% (+5.1% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 67th percentile. MRS_5 at 1.8% confirms short-term momentum alignment. Below SMA200 (0.89x), long-term trend not supportive. MACD histogram positive (1.76), confirming momentum. RSI neutral at 54. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.44% (CS: 68) | Strong |
| RSI_14 | 54.2 | Neutral |
| MACD Histogram | 1.76 | Bullish |
| vs SMA20 | 1.026x | Above |
| vs SMA50 | 0.998x | Below |
| vs SMA200 | 0.894x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $217.02
- **Stop Loss:** $206.08 (5.0% risk)
- **Target:** $227.96 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 109
- **Position Value:** $23,655.18
- **Portfolio %:** 23.66%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | MOMENTUM (Zone F) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $2.04)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.94 | $2.04 | +5.3% |
| 2025Q2 | $1.92 | $2.00 | +4.1% |
| 2025Q1 | $1.40 | $1.53 | +9.0% |
| 2024Q4 | $2.10 | $2.12 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*